| | Indust | ry | |
|--|--------|---------------|--------------|
| <u>Richard P</u> | . Wenz | <u>el, MD</u> | <u>, MSc</u> |
| <u>Company</u> <u>Research</u> <u>Consulting</u> | | | |
| Rib-x | | | |
| Pfizer | | | |
| 3M | | | |
| Boerhinger Ing | elheim | | |
| Biomerieux | | ▲ | |
| Sanofi-Aventis | | | |
| Vestagen | | | |



H1N1 in Mexico and South America Onsite Observations and Impressions (A H1N1/swine/California/004/2009)

Richard P. Wenzel, M.D., M.Sc. Professor and Chairman Department of Internal Medicine Medical College of Virginia Virginia Commonwealth University Richmond, Virginia





















A Case in Oaxaca

39 ♀

- 9 April resp distress CAP
- 10 ARDS
- 12 Call to fed health
- coronavirus ? SARS
- 13 death- C-R failure
- 23 confirmed H1N1 (swine)



March 5 • La Gloria – 4 cases ILI March 4 • San Luis – 4 cases

| | | <u>Res</u> <u>The T</u> | sponse t 'imeline | o H1N in Me | <u>1</u> <u>xico</u> | |
|--------------------------|------|-------------------------------------|--|-----------------------------------|---|-----|
| La Glori 640 cases | • C | all from Oax • Informal • Und | aca calls from II ersecretary of |) doctors f Health vis | its hospitals | |
| | | | • New I Mexic | H1N1 – Wi co announc • Epic | nnipeg lab es epidemic lemic peaks | |
| 1 | 0 14 | 17 18 April | 24 | 30 | • Some soc activities resume 11 May | cia |







<u>Respiratory Disease Institute –</u> <u>May 2009</u>

Background flu season pneumonias

20/week 2007-8/2008-9

At peak end of April: 120/week – six times background!

Prevalence at peak 20 patients - most on vent

Mean age 26

 \geq 80% dyspnea, cough, malaise

12% diarrhea (6 x/d)







Fever and H1N1 in Mexico/Chile

- Almost all severe cases have fever at triage
- One third of milder cases have no fever at triage
- ~ half of them do not have fever after admission
- Chile:
- ~half of confirmed H1N1 in clinics have no fever
- China one third hospitalized had
- no fever NEJM 2009; 361:2507-17



Implications of Absence of Fever and H1N1

- Underestimate impact of epidemic
- Limit value of thermal scans
- Difficulty of control especially in children (shedding)
- Infection control must be assiduous





CASE 1

- ID: 22 yo male, Mexico City resident.
 FH: HTN and Diabetes
 Social Hx: no animal contact, Smoke (+), close contact with 5 persons
- PMH: obese



| | | k | ZVOI | LUT | ION | |
|--|---------------------------|---------------------|----------|-------|-----------------|--|
| Emerge | ency Roo | om | | 0 | Laboratory Data | |
| April | 14th | | | | April 14th | |
| HR 113, RR 3 | 84, TA 13 | 0/80, | CBC | 04/24 | | |
| T° 38.2 SaO2 | 86%. | | WBC | 1.8 | | |
| Obese, increa | ased wo | rk of | PMN | 79% | | |
| breathing, hypov bilateral crackles | entilated R , ФМRG, re | LB, with st wnl. | Lymp | 12% | | |
| | | | Mon | 8.0% | | |
| ABG | 04/24 | | Eos | 0.3% | | |
| pH | 7.4 | | Bas | 0.0 | | |
| pCO2 | 41.0 | | Bands | 0.0 | | |
| pO2 | 56 | | HB | 16.6 | | |
| SaO2 | 86% | | Hto | 48.4 | | |
| Kirby | 200 | | Platelet | 80 | | |







| E | VOLUT | ION | | | |
|---|---------------|----------|-------|-------|-------|
| | ICU | | | | |
| Apri | l 15th – 24th | | | | |
| RESPIRATORY: volume control, PEEP 14 FiO2 100% SaO2 80% | | CBC | 14/04 | 15/04 | 24/05 |
| Pronnated | | WBC | 1.8 | 5.7 | 5.3 |
| CARDIOVASCULAR: required | | PMN | 79% | 94.8 | 76.2 |
| vasopressor support (NE). | April 18th: | Lymp | 12% | 4.6 | 11.8 |
| ID: febrile for 2 days. | Tx: | Mon | 8.0% | 0.6 | 10.5 |
| April 20th 2 hypothermid | oseltamivir. | Eos | 0.3% | 0.1 | 0.2 |
| Blood cultures: (-) | April 20th | Bas | 0.0 | 0.0 | 0.5 |
| Legionella/Pneum Ag (-) | | Bands | 0.0 | 0.0 | 0.0 |
| HIV negative | | нв | 16.6 | 13.7 | 12.8 |
| | | Hto | 48.4 | 40.5 | 36.7 |
| Bronchoscopy: mucosal edema. | | Platelet | 80 | 90 | 311 |

















<u>Pregnancy, Obesity are Risk</u> Factors for Severity of H1N1

- Brazil Pregnancy: number one cause for ICU admission more than obesity
- Columbia 1 of 7 deaths in pregnant women
- Chile Equal to obesity as risk for ICU admission
- Argentina one of 4 who died in Buenos Aires (n=85) was pregnant, just above obesity.
- U.S. 13% deaths in pregnant women

H1N1 and Obese Patients in ICU-Michigan

10 patients – median age 46 All on ventilator; 2 ECMO None had bacterial infection 9/10 – BMI> 30 7/9 BMI>40 5/10 – pulmonary emboli 9/10 MODS 3 deaths

U.S. Study (n=272) 45% obese/morbidly obese *NEJM* 2009; 361, in press

MMWR July 10, 2009

Ethnicity and H1N1 Risk

U.S.: hispanics (30%) and blacks (19%) overrepresented in hospitalized cases *NEJM* 2009: 361:1935-44

Aust/NZ: Indigenous in Australia (10%) and NZ (25%) overrepresented in ICU cases *NEJM* 2009; 361:1925-34 Canada: aboriginals (26%) overrepresented in ICU cases *JAMA* 2009 Oct 12 epub Aboriginals: independently predicted severity *CMAJ* 2010. doi:10.1503/cmaj.091884

Organ Transplant Patients Have Severe Outcomes

Argentina - ID Physicians have consistant observations Chile – 7 year old girl s/p liver transplant

acquired H1N1 in hospital

Mexico – H1N1 on hands, hard surfaces, computer mouse

Macias et al JHI in press

Implications for Infection Control

Sequelae of H1N1

- Post infections fatigue/myopathy 37%
- Need for Oxygen if O_2 in hospital 30%
- Night sweats weeks in some
- Late onset, reversible hair loss in some

Perez-Padilla Personal communication 07/2009

H1N1 ("Swine") Influenza What Was New

New virus – never seen before New cohort at risk – young adults New season – mid-spring New continent – Northern hemisphere New virulence – in Mexico ARDS/deaths



 In Mexico ARDS/dea confirmed in Chile, Argentina Young adults dying

Two Strategies for Influenza

- 1. Accumulation of point mutations with no proofreading
- Reassortment of 8 segments of RNA – "Viral Sex": exchange of genes of 2 viruses coinfecting a host (256 possible offspring)





Science 8 May 2009 324 : 701

| Reserve | oir fo | or influ | <u>enza is</u> | in |
|---------------|----------|----------|----------------|----------|
| <u>mig</u> | rator | ry wate | <u>r fowl</u> | |
| | | | | |
| ш | Ť | | | × |
| H2 | † | | | × |
| H3 | ţ | | 1 | × |
| H4 | | | | × |
| H5 | Ť | | | <u>×</u> |
| H7 | Ť | | ~~ | × |
| H9 | Ť | | | × |
| H6,H8, H10-16 | | | | × |
| H1N1 in tu | rkeys i | n Chile | | |



Diarrhea and H1N1

12% of cases in Mexico City

10-20% of cases – Chile

Virus found in stool in Mexico

- Implications: additional Infection control
- Is the GI tract the source of pro-inflammatory response?

Staph aureus Pneumonia - 1918

8100 **c** flu 1409 pneumonia (17% 385 died (27%)

~half of deaths (153) with S. aureus cults 92 of 153 (60%) S aureus only

56% deaths by day 10, 72% by 15



Chickering & Park JAMA 1919; 72:617-26

Cherry red indigo blue

Co-Infection H1N1 and CA-MRSA





Histopathology of pandemic A (H1N1)/cMRSA co-infection PLoS ONE 5(1): e705.doi:10.1371/journal.pone.0008705

<u>Controlling an Epidemic</u> <u>Mexico City</u>

- Social distancing
- Psychological support for HCWs/families
- Triage patient/with patients
- Reeingeneering of hospital
- Infection control

"Social Distancing"

Close all: schools restaurants bars football (soccer) games malls theaters swimming pools No embraces, kissing, handshaking Open – grocery stores Suggest – "stay home" No ties in Mexico city wear masks in public No data for any aspect of social distancing

<u>Managing Fear Among</u> <u>HCWs/families</u>

Anecdotes – ID personnel Consultations and fear more if not ID Converse with HCWs 24/7 access to special care clinic 24/7 hotline "We will take care of you"







Infection Control

Handwashing, gloves, mask "Don't touch your face" Cohort nurses with specific patients during day Triage HCWs/patients Cohort patients with respiratory symptoms

Interrupting the Spread of Influenza: Meta-Analysis of 6 Case-Control Studies

| Intervention | No studies | OR (CI ₉₅) | NNT |
|-----------------------|---------------|------------------------|-----|
| Handwashing ≥10 x/day | 6 | 0.45 (.3657) | 4 |
| Wearing masks | 5 | 0.32 (.2540) | 6 |
| Wearing N-95 masks | 2 | 0.09 (.0330) | 3 |
| Wearing gloves | 4 | 0.43 (.2965) | 5 |
| Wearing gowns | 4 | 0.23 (.1437) | 5 |
| HW/masks/gloves/gown | 2 | 0.09 (.0235) | 3 |

BMJ 2009; 339:63675 doi:10.1136/bmj b3675



Influenza Pathogenesis



• Incubation 1-4 d • 50% cases asymptomatic (still shedding) •Adults – shed virus 3-5 d •Young children shed virus to 3 weeks •Immune compromised shed virus > 3 weeks

NEJM 1966; 274:527-35 JID 1979; 140:610-3 Ped Inf Dis 1999; 18:811-5



Boeing 737



Am J Epidemiol 1979; 110:1-6







Is It Possible to Control Influenza?

- Large droplets
- Droplet nuclei
- Environmental contamination
- Shedding in adults/children
 - Mild cases without fever
- Virus in stool

<u>N-95 vs Surgical Masks for</u> <u>Influenza Control</u>

For HCWs



- Influenza virus .08-.12 microns
 N-95 testing .3 micron particles
- Experimental model (N-95) using bacteriophage .02 microns -95 to 96% effective
- Surgical masks 15%-80%
 AJIC 2006; 34:51-7
- 9 patients with influenza Neg PCR – 20 cm from coughing X 5 *CID* 2009; 49:215-7



Antiviral Treatment of Influenza – H1N1



Dosage in adults Approved: 75 mg bid x 5 Consider 150 mg bid x 10

9 cases of Resistance – U.S. MMWR 9/11/09

2 inhalations of 5 mg each bid x 5 Diskhalar inhalation device

Most strains are highly resistant to M2 inhibitors – amantadine and rimantadine

Under study: peramivir, ribavirin, interferon alpha NEJM 2005; 353:1374-85 AAC 2001; 45:2723-32 JID 2005; 192:665-72

<u>Neuraminidase Inhibitors: Updated Cochrane</u> <u>Systematic Review – Meta-analysis</u>

Prophylaxis against influenza Zanamivir reduced symptomatic, lab confirmed flu (0.38; 0.17-.85) Oseltamivir similar (0.39; .18-.85) *Neither drug protected against asymptomatic illness Post-exposure prophylaxis (households) 2 trials – Zanamivir: 0.19 and 0.2 2 trials – Oseltamivir: 0.16 and 0.42 Treatment – 8 trials Zanamivir and 5 Oseltamivir reduce symptoms (mild illness) 1 day

BMJ 2009; 339:65106 doj:10.1136/bmj.65106

Key Points: NIs

- 1. NIs reduce symptoms modestly by ~ 1 day
- 2. No data that the benefits are same for ill, hospitalized
- 3. NIs do not prevent infection or stop nasal viral excertion:

suboptimal for interrupting a pandemic.

4. Authors Jefferson et al do not recommend for routine control of seasonal influenza.

BMJ 2009; 339:65106 doj:10.1136/bmj.65106

<u>Models of 2009 H1N1 Suggest</u> <u>Value of Early Treatment with NIs</u>

ARDS and H1N1:

older age, high APACHE II and SOFA scores, and delay of initiation of oseltamivir linked to mortality Ann Fr Anesth Reanim 2010, Jan 28, epub Hospitalized patients with pneumonia (Taiwan) Development of respiratory failure linked to SOFA \geq 4 on admission, lymphocyte count \leq 800 c/mnL and duration of symptoms to initiation of oseltamivir \geq 48 h J Infect 2009 (Dec 29) epub Predicting admission to ICU among pregnant patients \geq 2 days after symptoms to initiate of antivirals (RR4.3) NEJM 2010; 362:27-35

Unanswered Questions

- Any role for anti-inflammatory agents eg human activated protein C?
- If huge pro-inflammatory response, role for exchange transfusion? IVIG? Mesalazine?
- ♦Will virulence change?
- Added value with intravenous Zanamivir or Peramivir?
- ♦ Will H1N1 recur as a 'seasonal' virus?

Unanswered Questions

Steroids – when/dose/may ↑ shedding of virus Value of aerosolized NIs – may plug tubing! no data. Can obstruct filter! have tried in severe cases plus oral oseltamavir Value of ECMO?





Future Issues

- ✤ Failure to admit patients to ICU initially
- ♦ Complacency!
- Communication
 - Credible, factual, clear
 - Do not overpromise
- * Rapid availability of cell-based vaccines
- * Response implications for bioterror





Pandemics in Perspective

| Case Mortality-Estimates | | Deaths in terms of current population in the US | | |
|-------------------------------|-----------|---|---------|--|
| "Spanish" | 2.5% | | 900,000 | |
| 1957 "Asian" | 0.2 -0.5% | } | 180,000 | |
| 1968 "Hong Kong" | 0.2-0.5% | J | | |
| Annual influenza epidemics | 0.1% | | 36,000 | |



WHO Declares H1N1 a "Pandemic 6"

Pandemic: sustained spread in different continents?

- Q: What is different?
 - Seasonal flu kills 500,000 and no pandemic 6 level
- Suggest: stratify levels by surge capacity needed for resources, communication and cooperation
- Thus, key elements are transmissibility and severity

RP Wenzel – Huffington blog 16 June 2009

Droplets and Droplet Nuclei in Influenza: Volunteer Studies

> 10 µm

::.



droplet administration

⇒Milder disease in volunteers, required larger inoculum

 $< 10 \ \mu m$ Droplet nuclei

• more likely to cause infection of lower respiratory tract

J Immunol 1945; 52:145-65 Proc Soc Exp Biol Med 1966; 122:800-4 Soc App Bact Symp Ser 1974; 3:135-54

CASE 1

- ID: 22 yo male, Mexico City resident.
 FH: HTN and Dist
- FIT: HTN and Diabetes Social Hx: no animal contact, Smoke (+), close contact with 5 persons
- PMH: Obese

CC: "Fever and cough".

History of present illness: onset of fever (39.0°C), CHILLS, malaise & fatigue and productive COUGH on April 9th. The patient was seen on an OSH and was treated with penicillin and pain medication. During his follow-up he presented with DYSPNEA and PLEURITIC CHEST PAIN; he was further treated with IM ceftriaxone.





| | <u>10 Confirmed Cases in Vietnam</u> |
|---|--|
| | Mean age: 13.7 years (5-24 years) 9 of 10 had direct contact with poultry (mean 3 days before) |
| | All had fever (38.5-40°C), shortness of breath, cough 7 of 10 had diarrhea - + virus |
| | Respiration: 55 breaths/min (20-70) All had rales |
| V | lean laboratory values: Hemoglobin |
| | Fotal V2.5 g/uL/ Platelet count 8 of 10 (80%) died 2100 mm ³ 75,500 mm ³ |

RADIOLOGIC IMAGES







As of May 12, WHO reported 4694 cases worldwide, including Finland, Cuba and Thailand





Not unusual to see coinfections with seasonal flu

ID Physicians in Argentina think coinfections overrepresented in severe cases (July 09 – "Winter")

Implications for Infection Control

Triage at Entrance - Outside

At peak – 1500 patients/day 20% arrive by bus Elicit symptoms Lung exam If no flu-like illness and non-essential – go home If flu-like – cohort after alcohol hw/mask If no flu-like illness – separate room

<u>Children (< 18 years) with H1N1-</u> <u>U.S.</u>

- 36 (7.5%) 977 deaths in U.S.
- 7/36 (19%) < age 5
 - 24/36 (67%) hi risk
 - 22/24 (92%) neuro developmental disease
 - 10/23 (43%) bacterial coinfection

MMWR, Sept 4, 2009